CJJ300 is a transforming growth factor-β ( TGF-β ) inhibitor with an IC 50 of 5.3 µM. CJJ300 inhibits TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex In Vitro CJJ300 disturbs protein-protein interactions and prevents TGF-β receptor dimerization (IC 50 = 23.6 ± 5.8 µM). CJJ300 (0-80 µM, 2 h) inhibits the phosphorylation of intracellular mediators in the downstream TGF-β signaling pathways, and suppresses the expression of markers of EMT (epithelial-mesenchymal transition) without cytotoxicity. CJJ300 suppresses TGF-β induced cell migration. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: Human A549 lung epithelial cells Concentration: 20, 40, and 80 µM Incubation Time: 2 h Result: Significantly attenuated the increasement of P-Smad2/Smad3, P-Erk1/2 and P-Akt induced by TGF-β. Down regulated the expression of EMT-associated proteins, including fibronectin, α-SMA and MMP-2 in a dose-dependent manner. Form:Solid IC50& Target:IC 50 : 5.3 µM (TGF-β1-induced luciferase)